ClinicalTrials.gg

Program

mosunetuzumab

Also written as “Mosunetuzumab”, “Mosunetuzumab (IV)” and “Mosunetuzumab (SC)”.

Its studies are mostly in Lymphoma, Follicular · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lupus Nephritis, led by 2 companies.

Furthest: phase 3, since Jan 13, 202114 company-led studies, 7 open or runningNext primary completion: Jul 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche137 open or runningphase 3since Jan 13, 2021Jul 14, 2015Jul 31, 2027phase 2 · NCT05207670
Ipsen10 open or runningphase 2since Dec 29, 2021Dec 29, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2015First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to Hoffmann-La RocheHoffmann-La Roche · NCT02500407 · 713 enrolled · United States, Australia, Canada and more
  2. Sep 10, 20183 phase 2 studiesHoffmann-La Roche · NCT03671018, NCT03677154, NCT03677141
  3. Jan 27, 2020Phase 2 study in Lymphoma, FollicularHoffmann-La Roche · NCT04246086 · 237 enrolled · United States, China, France and more
  4. Mar 17, 2020Phase 1 study in Lymphoma, B-CellHoffmann-La Roche · NCT04313608 · 23 enrolled · Australia
  5. Jan 13, 2021Phase 3 study in RecurrenceHoffmann-La Roche · NCT04712097 · 478 enrolled · United States, Australia, Brazil and more
  6. Oct 12, 2021Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellHoffmann-La Roche · NCT05091424 · 332 planned · United States, Australia, China and more
  7. Dec 6, 2021Phase 3 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT05171647 · 208 enrolled · United States, Argentina, Brazil and more
  8. Dec 10, 2021Phase 1 study in Lupus Erythematosus, SystemicHoffmann-La Roche · NCT05155345 · 15 enrolled · United States, Moldova, Republic of, Poland
  9. Dec 15, 2021Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT05207670 · 320 enrolled · United States
  10. Dec 29, 2021Ipsen's first study: phase 2 study in Hematologic NeoplasmsNew to IpsenIpsen · NCT05205252 · United States
  11. Mar 31, 2022Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT05315713 · 8 enrolled · United States, Australia, Belgium and more
  12. Feb 2, 2026Phase 2 study in Lupus Erythematosus, SystemicHoffmann-La Roche · NCT07598396 · 30 planned · Argentina, Brazil, Colombia and more
  13. Nov 16, 2026Primary completion moved from 2028-02-28 to 2028-08-11Date moved laterphase 2 · +5 months · NCT07598396

Ahead

  1. Jul 31, 2027Primary completion: phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT05207670
  2. Aug 11, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicHoffmann-La Roche · NCT07598396
  3. Sep 6, 2030Primary completion: phase 2 study in Lymphoma, FollicularHoffmann-La Roche · NCT04246086
  4. Feb 10, 2031Primary completion: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellHoffmann-La Roche · NCT05091424

TargetBeta

CD3E →MS4A1 →read by rule
“T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
GSK5926371GlaxoSmithKlinephase 22
REGN9220ruleRegeneron Pharmaceuticalsphase 21
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 13

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07598396Lupus Erythematosus, Systemic · Argentina, Brazil, Colombia and more2RecruitingHoffmann-La RocheAug 11, 202830
NCT05315713Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more2TerminatedHoffmann-La RocheJul 19, 20238
NCT05205252Hematologic Neoplasms · United States2WithdrawnIpsenJul 5, 20230
NCT05207670Lymphoma, Non-Hodgkin · United States2Active, not recruitingHoffmann-La RocheJul 31, 2027320
NCT05155345Lupus Erythematosus, Systemic · United States, Moldova, Republic of, Poland1CompletedHoffmann-La RocheDec 17, 202415
NCT05171647Lymphoma, Non-Hodgkin · United States, Argentina, Brazil and more3Active, not recruitingHoffmann-La RocheFeb 17, 2025208
NCT05091424Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, China and more1RecruitingHoffmann-La RocheFeb 10, 2031332
NCT04712097Recurrence · United States, Australia, Brazil and more3Active, not recruitingHoffmann-La RocheJun 3, 2026478
NCT04313608Lymphoma, B-Cell · Australia1CompletedHoffmann-La RocheOct 26, 202123
NCT04246086Lymphoma, Follicular · United States, China, France and more2Active, not recruitingHoffmann-La RocheSep 6, 2030237
NCT03677154Lymphoma, Large B-Cell, Diffuse · United States, Israel, Poland and more2CompletedHoffmann-La RocheAug 7, 2025188
NCT03677141Lymphoma, B-Cell · United States, Austria, France and more2CompletedHoffmann-La RocheOct 12, 2023117
NCT03671018Lymphoma, B-Cell · United States, Belgium, Canada and more2Active, not recruitingHoffmann-La RocheJan 30, 2024422
NCT02500407Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Canada and more2CompletedHoffmann-La RocheMay 21, 2024713

How it is read

Names in the registry

  • “Mosunetuzumab”, 8 entries
  • “Mosunetuzumab (IV)”, 2 entries
  • “Mosunetuzumab (SC)”, 2 entries
  • “Mosunetuzumab (Cohorts A-C)”, 1 entry
  • “Mosunetuzumab (Cohorts D-E)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.